401567-11-1

Basic information

• Product Name: 2H-Benzimidazol-2-one,5-fluoro-1,3-dihydro-1-methyl-(9CI)
• Synonyms: 2H-Benzimidazol-2-one,5-fluoro-1,3-dihydro-1-methyl-(9CI)
• CAS NO: 401567-11-1
• Molecular Formula: C₈H₇FN₂O
• Molecular Weight: 166.1523832
• Product Categories: BENZIMIDAZOLE
• Mol File: 401567-11-1.mol

Chemical Properties

• Appearance: /
• Density: 1.315±0.06 g/cm3(Predicted)
• PKA: 11.20±0.30(Predicted)
• CAS DataBase Reference: 2H-Benzimidazol-2-one,5-fluoro-1,3-dihydro-1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazol-2-one,5-fluoro-1,3-dihydro-1-methyl-(9CI)(401567-11-1)
• EPA Substance Registry System: 2H-Benzimidazol-2-one,5-fluoro-1,3-dihydro-1-methyl-(9CI)(401567-11-1)

Safety Data

• Hazardous Substances Data: 401567-11-1(Hazardous Substances Data)

Usage

Type

Fluorinated derivative of benzimidazol-2-one

Substitutions

5-fluoro substitution at the 1-position
1-methyl substitution at the 3-position

Structure

Heterocyclic organic molecule

Potential Pharmaceutical Applications

Biological activities related to its structural features
Interactions with enzymes or receptors in the body

Need for Further Research

To fully understand the properties and potential uses of this chemical.

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 401567-10-0 4-fluoro-N₁-methylbenzene-1,2-diamine 
• 704-05-2 (4-fluoro-2-nitrophenyl)-(methyl)amine 
• 364-74-9 1,4-difluoro-2-nitrobenzene 
• 131780-97-7 (4-Fluoro-2-nitro-phenyl)-methyl-amine 
• 201849-15-2 2-bromo-1-chloro-4-fluoro-benzene 
• 598-50-5 N-Methylurea 

Downstream Products

• 401567-12-2 2-chloro-5-fluoro-1-methyl-1H-benzimidazole 

Relevant articles and documents

1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).

Selective: S -arylation of 2-oxazolidinethiones and selective N -arylation of 2-benzoxazolinones/2-benzimidazolinones

There exist three possible patterns for the reaction of cyclic 2-oxazolidinethione and 2-benzoxazolidinethione with arynes, namely (a) S-arylation, (b) N-arylation, and (c) aryne insertion into the thiocarbonyl group (CS). Our studies demonstrate that S-arylation wins out affording S-aryl dihydrooxazoles. In contrast, for related reactions of cyclic 2-benzoxazolinone and 2-benzimidazolinone with arynes, it is found that N-arylation outcompetes O-arylation and aryne insertion into the CO group to give N-aryl 2-benzoxazolinones and N-aryl 2-benzimidazolinones.

1,3-dimethyl benzimidazolones are potent, selective inhibitors of the brpf1 bromodomain

The BRPF (bromodomain and PHD finger-containing) protein family are important scaffolding proteins for assembly of MYST histone acetyltransferase complexes. Here, we report the discovery, binding mode, and structure-activity relationship (SAR) of the firs

Regioselective synthesis of benzimidazolones via cascade C-N coupling of monosubstituted ureas

A direct method for the regioselective construction of benzimidazolones is reported wherein a single palladium catalyst is employed to couple monosubstituted urea substrates with differentially substituted 1,2-dihaloaromatic systems. In this method, the catalyst is able to promote a cascade of two discrete chemoselective C-N bond-forming processes that allows the highly selective and predictable formation of complex heterocycles from simple, readily available starting materials.

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain at least one EP4 receptor antagonist (2), in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryland wherein R1 and R2 have the meanings given in claim 1, the preparation thereof and the use thereof for the treatment of respiratory complaints.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new dihydrothienopyrimidinesulphoxides of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partially saturated or saturated heterocycle or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings stated in claim 1, as well as pharmaceutical compositions which contain these compounds. These new dihydrothienopyrimidinesulphoxides are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof

The present invention relates to enantiomerically pure compounds of formula 1 wherein the groups m, n, B, X, R1, m and Ym- may have the meanings given in the claims and specification, methods for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

Medicament Combinations for the Treatment of Respiratory Diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R1, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.